Goldstream Capital Management Ltd Acquires 3,729 Shares of Eli Lilly and Company (NYSE:LLY)

Goldstream Capital Management Ltd lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 190.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,685 shares of the company’s stock after purchasing an additional 3,729 shares during the quarter. Eli Lilly and Company comprises 2.2% of Goldstream Capital Management Ltd’s investment portfolio, making the stock its 15th biggest holding. Goldstream Capital Management Ltd’s holdings in Eli Lilly and Company were worth $3,314,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Montis Financial LLC boosted its position in shares of Eli Lilly and Company by 9.4% during the fourth quarter. Montis Financial LLC now owns 464 shares of the company’s stock valued at $271,000 after purchasing an additional 40 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of Eli Lilly and Company by 49.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 8,294 shares of the company’s stock valued at $4,834,000 after purchasing an additional 2,746 shares in the last quarter. Aveo Capital Partners LLC boosted its position in shares of Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after purchasing an additional 153 shares in the last quarter. Levin Capital Strategies L.P. boosted its position in shares of Eli Lilly and Company by 3.8% during the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after purchasing an additional 15 shares in the last quarter. Finally, Intelligence Driven Advisers LLC boosted its position in shares of Eli Lilly and Company by 40.2% during the fourth quarter. Intelligence Driven Advisers LLC now owns 1,300 shares of the company’s stock valued at $839,000 after purchasing an additional 373 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY traded down $20.94 during trading on Friday, hitting $734.97. The company’s stock had a trading volume of 4,535,213 shares, compared to its average volume of 3,087,178. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78. The firm has a market cap of $698.52 billion, a PE ratio of 108.24, a P/E/G ratio of 1.57 and a beta of 0.37. The business’s 50 day simple moving average is $761.75 and its 200-day simple moving average is $670.56.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the firm earned $1.62 earnings per share. The company’s quarterly revenue was up 26.0% on a year-over-year basis. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on LLY shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a report on Wednesday. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, Truist Financial increased their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.